Your browser doesn't support javascript.
loading
Limited prognostic value of c-erbB-2 compared to uPA and PAI-1 in primary breast carcinoma.
Bouchet, C; Ferrero-Poüs, M; Hacène, K; Becette, V; Spyratos, F.
Afiliación
  • Bouchet C; Department of Biology, Centre René Huguenin, St-Cloud, France.
Int J Biol Markers ; 18(3): 207-17, 2003.
Article en En | MEDLINE | ID: mdl-14535592
In a retrospective study of 488 women with primary breast cancer, after a median follow-up of 10 years, we sought interactions between disease-free survival (DFS) and overall survival (OS) and tumor antigen levels of two components of the plasminogen system, urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1, and the transmembrane growth factor receptor c-erbB-2. We used ELISAs (American Diagnostica, Greenwich, CT, USA) to quantify uPA and PAI-1 antigen levels in cytosols, and a double monoclonal antibody-based assay (EIA) (Ciba Corning Diagnostics, Alameda, CA, USA) to quantify c-erbB-2 in membrane extracts of the same tissues. Weak positive correlations were found between uPA and c-erbB-2 (r(s) = 0.146; p = 0.001) and between PAI-1 and c-erbB-2 (r(s) = 0.154; p < 0.001). In the overall population, using univariate analyses, c-erbB-2 overexpression and high uPA and PAI-1 antigen levels (> 300 IU/mg, > 1.40 ng/mg and > 5.53 ng/mg, respectively) were significantly associated with shorter DFS (p = 0.003, p < 0.001 and p < 0.001, respectively) and OS (p < 0.001 in all cases). Using multivariate analyses, PAI-1, node status and tumor size were independent predictors of DFS and c-erbB-2 was retained in the model only for OS. In the node-negative subgroup, PAI-1 was the strongest significant survival predictor both for OS (p = 0.003; HR 2.52) and DFS (p < 0.001; HR 2.39). This study shows that in primary breast cancer c-erbB-2 offers no additional prognostic information when uPA and/or PAI-1 are candidates in the multivariate analyses.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Activador de Plasminógeno de Tipo Uroquinasa / Inhibidor 1 de Activador Plasminogénico / Receptor ErbB-2 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Int J Biol Markers Asunto de la revista: BIOQUIMICA / NEOPLASIAS Año: 2003 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Activador de Plasminógeno de Tipo Uroquinasa / Inhibidor 1 de Activador Plasminogénico / Receptor ErbB-2 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Int J Biol Markers Asunto de la revista: BIOQUIMICA / NEOPLASIAS Año: 2003 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos